Dr. Shijun Kang 康世均
Chief Physician, Associate Professor
Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of lung cancer using chemotherapy, targeted therapy, immunotherapy, radiofrequency ablation, and hyperthermic perfusion. Also treats esophageal cancer and breast cancer.
Dr. Kang is Chief Physician and Deputy Director of the Department of Oncology at Nanfang Hospital. A postdoctoral fellow at the University of Chicago and senior visiting scholar at UIC, Dr. Kang has practiced medical oncology since 1992. Research focuses on lung cancer, including clinical studies on radiofrequency ablation (RFA) starting in 1999.
Professional roles
- Chair, Guangdong Branch of Chinese Medical Association
- Chair, Lung Cancer Professional Committee, Guangzhou Anti-Cancer Association
- Deputy Head, Thoracic Oncology Group, Oncology Branch of Guangdong Medical Association
- Vice Chair, Hyperthermia and Radiofrequency Ablation Professional Committee, Guangzhou Anti-Cancer Association
Name order: in Chinese the family name comes first (Kang Shijun). Papers usually list the name as Shijun Kang or Kang S.
Selected publications
17 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Immunol Lett, 2022 (senior author): Lymphopenic condition enhanced the antitumor immunity of PD-1-knockout T cells mediated by CRISPR/Cas9 system in malignant melanoma. PubMed 36174769
- Nan Fang Yi Ke Da Xue Xue Bao, 2020 (senior author): [Interleukin-12 over-expression in malignant melanoma B16 cells reduces programmed death-1 expression on T cells in mice with immune reconstitution]. PubMed 32895201
- Cancer Sci, 2018 (senior author): Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer. PubMed 29675979
- Nan Fang Yi Ke Da Xue Xue Bao, 2018 (senior author): [Soluble PD-1 over-expression enhances the anti-tumor effect of senescence tumor cell vaccine against breast cancer cell growth in tumor-bearing mice]. PubMed 33177023
- J Exp Clin Cancer Res, 2018 (senior author): Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1. PubMed 29301578
- Cancer Immunol Immunother, 2013 (first author): A knockdown of Maml1 that results in melanoma cell senescence promotes an innate and adaptive immune response. PubMed 22864395
- Immunobiology, 2010 (first author): Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. PubMed 19450895
- Lipids, 2008 (first author): LysoPtdOH enhances CXCL16 production stimulated by LPS from macrophages and regulates T cell migration. PubMed 18830732
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion